

ANNUAL DECLARATION OF INTERESTS (ADoI)

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

Name: WRIGHT, Matthew

Title: Prof

Profession: Biochemistry

Current EFSA involvements: Member-ANS Panel 2014-2017 (ANS), Member-Application WG 2014-2017 (ANS), Vice-Chair-Re-evaluation of Food Additives other than Gums & Colours WG 2014-2017 (ANS)

| Nature of Activities | Period | Organisation | Subject matter |
|---|--------|--------------|----------------|
| I. Economic interest | | | NO INTEREST |
| II. Member of a managing entity or equivalent structure | | | NO INTEREST |
| III. Member of a scientific advisory entity | | | NO INTEREST |

| | | | |
|----------------------------------|-------------------|---|---|
| IV. Employment | 10/2006 - now | -Name: Newcastle University | Main employment - Teaching/research in Toxicology. My research is on the PXR in inflammatory diseases, such as primary biliary cirrhosis; the development of human hepatocytes for toxicological research (toxicology and drug metabolism studies); investigations into xenoestrogens and cholestatic liver disease. I have significant experience of developing and running undergraduate courses and make contributions to Pharmacology and Toxicology teaching at undergraduate level. I also make a significant contributions to and at postgraduate teaching. I also undertake third strand activity through the continued development of a recombinant human antibody protein to a surface protein on fibrogenic cells. |
| V. Occasional consultancy | | | NO INTEREST |
| VI. Research funding | 01/2015 - now | -Name: The European Foundation for Alcohol Research | Research project - The effect of alcohol on the absorption and toxicity of food chemicals via the gut |
| | 08/2014 - now | -Name: Medical Research Council | A novel target to reduce graft failure in liver transplantation |
| | 08/2014 - now | -Name: University of Newcastle upon Tyne, UNITED KINGDOM, Newcastle upon Tyne | Nature and Nurture: Linking causative agents in the environment with increased incidence of primary biliary cirrhosis. |
| | 01/2014 - now | -Name: NIHR | Health Protection Research Unit – theme lead for “Chemical Exposures and the Development of Primary Biliary Cirrhosis |
| | 08/2012 - now | -Name: Medical Research Council | ITTP studentship. Investigating the Adverse Effects of Novel Tumour-specific IAP Antagonists. |
| | 08/2012 - now | -Name: Medical Research Council | Derivation of Human Hepatocytes from Pancreatic Progenitor Cells and their use in a Novel Antioxidant Screening Platform |
| | 08/2012 - now | -Name: Medical Research Council | Targeting MEK and VEGF inhibition to prevent melanoma metastasis and angiogenesis. |
| | 10/2011 - now | -Name: European Commission | Information and Communication Technology (ICT)-enabled, cellular artificial liver system incorporating personalised patient management and support (D-LIVER). |
| | 10/2011 - now | -Name: The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) | Applying the 3 R's to Liver Fibrosis Research. |
| | 08/2013 - 07/2014 | -Name: ARDF | Academic research funding consumables for a PhD studentship investigating the potential of an unlimited supply of rat hepatocytes in vitro/replacing animals as donors |
| | 10/2010 - 09/2013 | -Name: MRC (Case studentship with AstraZeneca) | Determination of mechanisms of flucloxacillin induced liver injury; translation to refining risk assessment screening. |
| | 10/2010 - 09/2013 | -Name: Medical Research Council | Myofibroblasts and their regulation of hepatic stem/progenitor cell function after injury |
| | 10/2009 - 09/2013 | -Name: Pfizer | Fund PhD studentships - Myofibroblasts and stem/progenitor cell function. |
| | 07/2012 - 06/2013 | -Name: Wellcome Trust | Production of functional hepatocytes from a progenitor cell line in vitro. |
| | 10/2008 - 09/2011 | -Name: British Toxicology Society, UK, Macclefield | Academic research indicating sunset yellow was a human estrogen receptor activator. |

| | | | |
|--|---------------|------------------------------------|--|
| VII. Intellectual property rights | 10/2007 - now | -Name: Pfizer | Previous employer (University of Aberdeen) IP protecting C1-3 antibody technology. I could receive personal financial benefit if the antibody is developed for use as a therapeutic in man. |
| VIII. Other memberships or affiliations | 06/2013 - now | -Name: In Vitro Toxicology Society | Member |
| | 12/2000 - now | -Name: British Toxicology Society | Member |
| | 10/1992 - now | -Name: Biochemical Society | Member |
| IX. Other relevant interest | | | NO INTEREST |
| X. Interests of close family members | | | NO INTEREST |

I hereby declare that I have read both the Guidance Document on Declarations of Interests and the Procedure for identifying and handling potential conflict of interests and that the above Declaration of Interests is complete.

Date: 02/02/2015 Signature: **SIGNED**